Orbital Causes of Ostiomeatal Complex Occlusion
- PMID: 40478163
- DOI: 10.1097/IOP.0000000000002965
Orbital Causes of Ostiomeatal Complex Occlusion
Abstract
Purpose: This study aimed to describe uncommon cases of ostiomeatal complex (OMC) occlusion and maxillary atelectasis secondary to orbital pathology.
Methods: A retrospective chart review of cases of ostiomeatal occlusion and maxillary atelectasis at a single institution was performed. Patients with an identifiable orbital cause were included, whereas patients with idiopathic occlusion (silent sinus syndrome) were excluded. Data collected included patient age, sex, clinical presentation, and measurements including exophthalmolmetry, radiographic features, interventions, and outcomes.
Results: Eight patients were identified with mechanical causes of ostiomeatal occlusion arising from the orbit. Five cases had malpositioned orbital floor implants in the setting of remote orbital reconstruction, including after trauma. Two cases had previous orbital decompression for thyroid eye disease with subsequent orbital mucocele and fat prolapse into the OMC. One case had distensible venous malformation of the inferior orbit resulting in occlusion of the OMC. The majority of patients required both endoscopic sinus surgery and treatment of the orbital pathology causing the OMC occlusion.
Conclusions: While rare, orbital pathology may cause OMC occlusion, which may lead to maxillary sinus atelectasis. Orbital surgeons should be aware of these associations and have a high index of suspicion when subclinical maxillary atelectasis is seen in conjunction with orbital pathology. Treatment may require addressing the underlying cause as well as multidisciplinary management of both sinus surgery to restore maxillary sinus ventilation and possible orbital reconstruction.
Copyright © 2025 The American Society of Ophthalmic Plastic and Reconstructive Surgery, Inc.
Conflict of interest statement
The authors have no financial or conflicts of interest to disclose relevant to this paper; other: D.O.K.—consultant for Amgen, Immunovant, Genentech, Acelyrin, and Lassen Therapeutics; Royalties: Elsevier. B.K.—Consultant: Amgen; Advisory Board: Acelyrin, Argenx, Immunovant, Viridian; Royalties: Elsevier. C.L.—Principal investigator for Lassen Therapeutics-sponsored clinical trial; Wolters Kluwers Health Royalties.
References
-
- Rosso C, Saibene AM, Felisati G, et al. Silent sinus syndrome: systematic review and proposal of definition, diagnosis and management. Acta Otorhinolaryngol Ital 2022;42:305–316.
-
- Vander Meer JB, Harris G, Toohill RJ, et al. The silent sinus syndrome: a case series and literature review. Laryngoscope 2001;111:975–978.
-
- Soparkar CNS, Patrinely JR, Cuaycong MJ, et al. The silent sinus syndrome: a cause of spontaneous enophthalmos. Ophthalmology 1994;101:772–778.
-
- Rose GE, Lund VJ. Clinical features and treatment of late enophthalmos after orbital decompression: a condition suggesting cause for idiopathic “imploding antrum” (silent sinus) syndrome. Ophthalmology 2003;110:819–826.
-
- Brown SJ, Hardy TG, McNab AA. “Silent sinus syndrome” following orbital trauma: a case series and review of the literature. Ophthalmic Plast Reconstr Surg 2017;33:209–212.
LinkOut - more resources
Full Text Sources
